Kyntra Bio, Inc. - Asset Resilience Ratio

Latest as of December 2025: 34.37%

Kyntra Bio, Inc. (KYNB) has an Asset Resilience Ratio of 34.37% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read KYNB total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

$41.11 Million

Cash + Short-term Investments

Total Assets

$119.59 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Kyntra Bio, Inc.'s Asset Resilience Ratio has changed over time. See Kyntra Bio, Inc. (KYNB) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Kyntra Bio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see KYNB stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$41.11 Million	34.37%
Total Liquid Assets	$41.11 Million	34.37%

Asset Resilience Insights

Very High Liquidity: Kyntra Bio, Inc. maintains exceptional liquid asset reserves at 34.37% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Kyntra Bio, Inc. Industry Peers by Asset Resilience Ratio

Compare Kyntra Bio, Inc.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sagimet Biosciences Inc. Series A Common Stock NASDAQ:SGMT	Biotechnology	63.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bio-Thera Solutions Ltd SHG:688177	Biotechnology	4.09%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Gubra A/S CO:GUBRA	Biotechnology	79.61%

Annual Asset Resilience Ratio for Kyntra Bio, Inc. (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Kyntra Bio, Inc..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	34.37%	$41.11 Million	$119.59 Million	--
2024-12-31	0.00%	$0.00	$214.53 Million	--
2023-12-31	28.78%	$121.90 Million	$423.53 Million	-14.87pp
2022-12-31	43.65%	$266.31 Million	$610.09 Million	+13.42pp
2021-12-31	30.24%	$233.97 Million	$773.82 Million	+29.25pp
2020-12-31	0.98%	$8.14 Million	$826.84 Million	-46.54pp
2019-12-31	47.53%	$407.49 Million	$857.40 Million	-12.90pp
2018-12-31	60.43%	$532.14 Million	$880.60 Million	+53.52pp
2017-12-31	6.91%	$62.06 Million	$898.65 Million	-10.00pp
2016-12-31	16.91%	$79.40 Million	$469.55 Million	+10.99pp
2015-12-31	5.92%	$27.85 Million	$470.57 Million	+2.95pp
2014-12-31	2.97%	$14.36 Million	$483.53 Million	-12.68pp
2013-12-31	15.65%	$46.48 Million	$296.95 Million	+15.27pp
2012-12-31	0.38%	$1.02 Million	$265.59 Million	--

pp = percentage points

About Kyntra Bio, Inc.

NASDAQ:KYNB USA Biotechnology

Market Cap

$28.09 Million

Market Cap Rank

#24086 Global

#5057 in USA

Share Price

$6.94

Change (1 day)

-0.14%

52-Week Range

$6.46 - $9.50

All Time High

$9.50